Research Papers:

Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer

Ariadna Giró-Perafita, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Maria Buxó, Joan Brunet, Gemma Viñas and Teresa Puig Miquel _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:74391-74405. https://doi.org/10.18632/oncotarget.20152

Metrics: PDF 1274 views  |   HTML 4686 views  |   ?  


Ariadna Giró-Perafita1,*, Ariadna Sarrats1,*, Ferran Pérez-Bueno1,2, Glòria Oliveras1,3, Maria Buxó4, Joan Brunet1,3, Gemma Viñas1,3 and Teresa Puig Miquel1

1New Terapeutics Targets Laboratory (TargetsLab), Department of Medical Sciences, University of Girona, Girona, Spain

2Pathology Department, Dr. Josep Trueta Hospital and Catalan Institute of Health (ICS), Girona, Spain

3Medical Oncology Department, Catalan Institute of Oncology (ICO), Girona, Spain

4Girona Biomedical Research Institute (IDIBGI), Girona, Spain

*These authors have contributed equally to this work

Correspondence to:

Teresa Puig Miquel, email: [email protected]

Gemma Viñas, email: [email protected]

Keywords: EGFR, breast cancer molecular subtypes

Received: January 25, 2017    Accepted: May 05, 2017    Published: August 10, 2017


Triple-Negative Breast Cancer (TNBC) has poor prognosis and no approved targeted therapy. We previously showed that the enzyme fatty acid synthase (FASN) was largely expressed in a small TNBC patients’ cohort and its inhibition synergized with cetuximab in TNBC preclinical mouse models. Here, we evaluated FASN and EGFR expression in a cohort of TNBC patients and we study their prognostic role and their association with clinico-histopathological features, intrinsic TNBC subtypes and survival.

FASN, EGFR, CK5/6 and vimentin expression were retrospective evaluated by Immunohistochemistry in 100 primary TNBC tumors. FASN expression was classified into high and low FASN groups. EGFR, CK5/6 and vimentin expression were used in TNBC intrinsic subtypes classification.

FASN was expressed in most of the TNBC patients but did not correlate with overall survival or disease-free survival in this cohort. High FASN group was significantly associated with positive node status. FASN expression was significantly higher in Basal-Like patients than in Mesenchymal-Like ones. EGFR expression was positive in 50% of the tumors, and those patients showed poorer DFS. Altogether, our findings provide a rationale for further investigation the prognostic role of FASN and EGFR expression in a larger cohort of TNBC patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20152